| 영문 | tuberculin test | 한글 | 튜베르쿨린검사 |
|---|---|---|---|
| 설명 | 많은 서로 다른 형태의 튜베르쿨린과 다양한 투여방법에 의한 모든 종류의 결핵 피부검사법. 현재 표준 시험법으로 되어있는 가장 신빙성있는 검사로는 PPD를 피내주사하는 방법망토우 검사이다. 피내주사후 48~72시간 후에 주사부위에 직경 10mm이상으로 보이며, 만져지는 홍반과 경화가 나타나면 양성이다. 성인에게는 일반적으로 중간 강도의 튜베르쿨린(5Tu)을 사용하며, 양성반응이 나타나면 결핵균에 이전에 감염되었거나 현재 감염되어 있다는 확정적 진단이 된다. 음성반응은 결핵이 없거나, 심한 결핵감염에 의한 피부알레르기가 있을 경우, 또는 면역억제를 나타내는 병, 예를 들면 호지킨병이나 사르코이드증 등이 합병된 경우이다. |
||
| 영문 | Papanicolaou smear(test) | 한글 | 파파니콜로 도말검사 |
|---|---|---|---|
| 설명 | 줄여서 팝도말검사(Pap smear)이라고 부른다. 여성의 자궁목암의 발생을 미리 알아보기 위해 시행하는 검사법으로 미국에서는 이 방법으로 현재 자궁목암발생에 의한 사망률을 현저히 낮추고 있다. 방법은 산부인과에서 시행하며, 여성의 자궁목에서 세포를 가져다가 도말하여 현미경으로 검사한다. 요즈음에 와서는 자궁목뿐 아니라 호흡기나 비뇨기 등 분비물을 도말하여 파파니콜로 염색을 하여 검사하는 것도 여기에 포함된다. (그림 P-3). |
||
| 영문 | glucose tolerance test | 한글 | 포도당견딤검사 |
|---|---|---|---|
| 설명 | 포도당견딤 검사란 당뇨병의 진단에 사용되는 검사로 당을 체내에 투여하고 시간 별로 혈액을 채취하여 혈당의 농도를 재어서 고혈당 여부를 조사하는 검사이다. 주로 경구포도당견딤검사(oral glucose tolerance test)를 많이 하는데 이것은 10~16시간의 금식 후에 채혈을 한번 한뒤에 도당 75g을 250~300mL의 물에 녹여 5분에 걸쳐서 마시게 하고 매시간 별로 채혈을 하여 혈당의 농도를 첵크한다. 공복시에 정맥에서 채혈하여 측정한 혈당이 140mg/dL이상이거나 포도당견딤 검사 2시간후의 혈당이 200mg/dL이상일 경우에는 당뇨병으로 진단을 한다. 그러나 이 검사를 실시할 경우에 주의해야 할 점은 검사전 3일간 하루에 150g이상의 탄수화물을 섭취해야 한다는 것과 검사도중에 운동, 흡연 등을 하지 않아야 한다는 것이다. |
||
| 영문 | blood test | 한글 | 혈액검사 |
|---|---|---|---|
| 설명 | 혈액형이나 질병 유무 따위를 알기 위하여 피를 뽑아 행하는 검사. 몸 전체의 장기나 조직에 병터가 있으면 이들 성분에 변화가 있게 되어 진단에 큰 도움을 준다. |
||
| NBI | neutrophil bactericidal index; no bone injury; non-battle injury |
|---|---|
| HS | Haber syndrome; half strength; hamstring; hand surgery; Hartmann solution; head sling; healthy subje... |
| SAP | sensory action potential; serum acid phosphatase; serum alkaline phosphatase; serum amyloid P; situs... |
| Bz-Ty-PABA test | N-Benzoyl-L-Tyrosyl-p-Amino-Benzoic Acid test = Bentiromide test = Tr... |
| DAT | delayed-action tablet; dementia Alzheimer's type; dental aptitude test; diacetylthiamine; diet as to... |
| serum disease | A hypersensitivity response (type III) to the injection of large amounts of antigen, as might happen when large amounts of antiserum are given in a passive immunisation. The effects are caused by the presence of soluble immune complexes in the tissues. (18 Nov 1997) |
|---|---|
| serum erythropoietin | <protein> Erythropoietin is a protein hormone which is produced by specialised cells in the kidneys. These cells are sensitive to low arterial oxygen concentration and will release erythropoietin when oxygen is low. Erythropoietin stimulates the bone marrow to produce more red blood cells (to increase the oxygen caring capacity of the blood). The measurement of this hormone in the bloodstream can indicate bone marrow disorders or kidney disease. Normal levels of erythropoietin are 0 to 19 mU/ml (milliunits per millilitre). Elevated levels can be seen in polycythaemia vera. Lower than normal values are seen in chronic renal failure. (27 Sep 1997) |
| serum factor VIII antigen | A test used to measure the activity of a blood clotting factor VIII (Von Willebrand factor). This test is usually used to monitor treatment of haemophilia. Abnormally low factor VIII assays may be seen in the following conditions: congenital deficiency of factor VIII (haemophilia), DIC and secondary fibrinolysis. This test may also be performed in the evaluation of Von Willebrand's disease. (27 Sep 1997) |
| serum-fast | 1. Pertaining to a serum in which there is little or no change in the titre of antibody, even under conditions of treatment or immunologic stimulation. 2. Resistant to the destructive effect of sera. Synonym: serofast. (05 Mar 2000) |
| serum ferritin | <protein> A test that measures the amount of ferritin, a major iron storage protein. This test reflects the amount of iron stored in the body. Higher than normal values can be seen in haemochromatosis. Normal values for males: 12 to 300 ng/ml, females: 10 to 150 ng/ml. (27 Sep 1997) |
| serum globulins | All blood proteins except albumin ( = serum albumin, which is not a globulin) and fibrinogen (which is not in the serum). The serum globulins are subdivided into alpha-globulins, beta-globulins, and gamma-globulins on the basis of their electrophoretic mobilities. (12 Dec 1998) |
| serum glutamic oxaloacetic transaminase | <enzyme> An enzyme present in hepatocytes (liver cells) and heart cells. SGOT is released into the blood in larger quantities in cases where the heart or liver becomes damaged. Increased levels are usually associated with heart attacks or liver disease. Some medications can also raise blood SGOT levels. Another name for this test is the aspartate aminotransferase or AST. (27 Sep 1997) |
| serum glutamic-oxaloacetic transaminase | <enzyme> An enzyme catalyzing the reversible transfer of an amine group from l-glutamic acid to oxaloacetic acid, forming alpha-ketoglutaric acid and l-aspartic acid; a diagnostic aid in viral hepatitis and in myocardial infarctions. Synonym: aspartate transaminase, glutamic-aspartic transaminase, glutamic-oxaloacetic transaminase, serum glutamic-oxaloacetic transaminase. (05 Mar 2000) |
| serum glutamic pyruvic transaminase | <enzyme> An enzyme that is found primarily in the liver. It is released into the bloodstream as the result of liver damage. Also called the alanine aminotransferase (ALT) or serum glutamic pyruvic transaminase (SGPT). (27 Sep 1997) |
| serum glutamic-pyruvic transaminase | <enzyme> An enzyme that is found primarily in the liver. It is released into the bloodstream as the result of liver damage. Also called the alanine aminotransferase (ALT) or serum glutamic pyruvic transaminase (SGPT). (27 Sep 1997) |
| serum hepatitis | <virology> A form of viral hepatitis, known as serum hepatitis, because it is commonly spread through contact with infected blood products (transfusion). May also be spread sexually or from mother to infant. Hepatitis B can cause a much more severe infection than hepatitis A and can occur as an asymptomatic carrier state, a chronic infection or as cirrhosis of the liver. Those at risk (IV drug abusers, health care workers, dialysis patients, transfusion recipients, homosexuals) should be immunised with hepatitis B vaccine. The virus is 42nm diameter, with an outer sheath enclosing inner 27nm core particle containing the circular viral DNA. Aggregates of the envelope proteins are found in plasma and are referred to as hepatitis B surface antigen (HBsAg, previously called Australia antigen). The virus can persist for long periods (and in asymptomatic carriers), association of integrated virus with hepatocellular carcinoma is now well established. (27 Sep 1997) |
| serum hepatitis virus | The type species of the genus orthohepadnavirus which causes human hepatitis b and is also apparently a causal agent in human hepatocellular carcinoma. The dane particle is an intact hepatitis virion, named after its discoverer. Non-infectious spherical and tubular particles are also seen in the serum. (12 Dec 1998) |
| serum immunofixation | A special laboratory technique that is used to identify specific proteins in the blood or urine. It has greatest application in the identification (and monitoring) of monoclonal proteins that are produced in conditions like Waldenstom's macroglobulinaemia and multiple myeloma. (27 Sep 1997) |
| serum immunoglobulin electrophoresis | A test that detects and measures the various immunoglobulins in the blood. In the normal assay no monoclonal antibodies are detected. In multiple myeloma and chronic lymphocytic leukaemia a single clone of lymphocytes can produce one type of immunoglobulin that is detected in the electrophoresis as monoclonal (made by one cell clone). (27 Sep 1997) |
| serum iron level | A test that measures the amount of iron (Fe ++) in the blood. The test is performed when iron deficiency is suspected. Normal serum iron is 60 to 170 mcg/dl. Increased levels may be seen in the following: haemochromatosis, haemolysis, haemolytic anaemia, hepatitis, liver necrosis, haemosiderosis, iron poisoning and lead toxicity. Lower than normal levels are seen in chronic GI blood loss, iron deficiency anaemia, insufficient dietary iron, malabsorption, chronic heavy menstrual bleeding, nephrosis and late pregnancy. (27 Sep 1997) |